Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations and Comprehensive Loss

v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Costs and Expenses:    
Research and development $ 85 $ 11,433
General and administrative 6,875 8,729
Impairment charges of goodwill and other intangible assets 2,093
Impairment charges of other assets 2,338
Total costs and expenses 6,960 24,593
Loss from operations (6,960) (24,593)
Change in fair value of warrant liability (3,161)
Gain on sale of assets 37
Other (expenses)/income, net (261) 262
Loss before tax (10,345) (24,331)
Income tax benefit 80
Net loss (10,345) (24,251)
Deemed dividend relating to warrant exchange [1] (618)
Net loss attributable to common shareholders $ (10,963) $ (24,251)
Net loss per share - basic $ (2.00) $ (4.98)
Net loss per share - diluted $ (2.00) $ (4.98)
Weighted average common shares outstanding - basic 5,474,129 4,865,829
Weighted average common shares outstanding - diluted 5,474,129 4,865,829
Other comprehensive gain, net of tax    
Unrealized gain on securities available-for-sale $ 221
Other comprehensive gain, net of tax 221
Comprehensive loss $ (10,345) $ (24,030)
[1] Deemed dividend represents the excess of fair value of common stock issued over the fair value of warrants immediately prior to exchange, which reduces income available to common stockholders used for the basic and diluted net loss per common share calculation.